Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Elena Guerini RoccoKathryn P GrayCaterina FumagalliMarta Rita ReforgiatoIsabella LeonePaola Rafaniello RavieleElisabetta MunzoneRoswitha KammlerPatrick NevenErika HitreGuy JerusalemEdda SimonciniAndrea GombosInes DeleuPer KarssonStefan AebiJacquie ChirgwinVincenzo Di LauroAlastair ThompsonMarie-Pascale GraasMeredith M ReganChristel FontaineSibylle LoiblJoaquín GaviláKatsumasa KuroiBettina MüllerSeamus O'ReillyAron GoldhirschGiuseppe VialeMassimo BarberisMarco ColleoniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Postmenopausal women with hormone receptor-positive early breast cancer harboring FGFR1 CNG had an increased risk of late recurrence despite extended therapy. FGFR1 CNG may represent a useful prognostic biomarker for late recurrence and a therapeutic target.